We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Comment & Response |

Treatment of Nonmelanoma Skin Cancer

Cesar E. Guerrero, MD1; Boni E. Elewski, MD1; Craig A. Elmets, MD1
[+] Author Affiliations
1Department of Dermatology, University of Alabama at Birmingham School of Medicine, Birmingham
JAMA Intern Med. 2013;173(22):2096-2097. doi:10.1001/jamainternmed.2013.10442.
Text Size: A A A
Published online


To the Editor Linos and colleagues1 inappropriately bundle elderly patients and patients with multiple comorbidities, urging clinicians to encourage patients with limited life expectancy (LLE) to choose nonsurgical treatment modalities for the treatment of nonmelanoma skin cancer (NMSC). As a group, patients older than 85 years may have limited life expectancy, but age alone does not separate those who will experience a quality-of-life (QOL) benefit from those who will not. The best predictor of posttreatment health-related QOL in an otherwise healthy 85-year-old patient is his or her pretreatment skin and health-related QOL.2 Linos et al1 use a nonvalidated survey to measure how bothered the patients are by their NMSC, failing to include tumors that are moderately bothersome. Furthermore, the author trivializes the patients’ perception of their skin cancer, stating that they are “low impact.”1 Previous work by Chen et al2 has demonstrated that among symptoms, emotional effects, and effects on functioning, emotional effects had the greatest impact on QOL for patients with NMSC. Although rarely fatal, NMSCs are cancer, and elderly but otherwise healthy patients of any age can experience a great deal of distress leaving skin cancer untreated.3 In addition, Linos et al1 argue that patients are unlikely to survive long enough to receive a benefit even when the majority of the patients in their study lived beyond 5 years.1 Not only do these statements mislead the reader, the author fails to acknowledge that the QOL benefits of treating NMSC can be measured at 12 months.2


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





December 9, 2013
Eleni Linos, MD, DrPH; Charles Seth Landefeld, MD; Mary Margaret Chren, MD
1Department of Dermatology, University of California, San Francisco
2Department of Medicine, University of Alabama, Birmingham
JAMA Intern Med. 2013;173(22):2097. doi:10.1001/jamainternmed.2013.10388.
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...